Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646 1674
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 18035472 | ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES | Non-Final OA | NOVARTIS AG |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | Non-Final OA | Novartis AG |
| 17751586 | CHIMERIC RECEPTORS TO FLT3 AND METHODS OF USE THEREOF | Final Rejection | Kite Pharma, Inc. |
| 18162955 | COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF | Final Rejection | Incyte Corporation |
| 17474389 | Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy | Non-Final OA | INOVIO PHARMACEUTICALS, INC. |
| 18219138 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17632157 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF CANCER | Final Rejection | Astellas Pharma Inc. |
| 18511308 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME | Non-Final OA | Immatics Biotechnologies GmbH |
| 18301545 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME | Final Rejection | Immatics Biotechnologies GmbH |
| 17950350 | INERT FORMAT | Non-Final OA | GENMAB A/S |
| 18272826 | GARP Protein Antibody and Use Thereof | Non-Final OA | JIANGXI JEMINCARE GROUP CO., LTD. |
| 17661841 | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) | Non-Final OA | AnaptysBio, Inc. |
| 17622341 | ANTIBODIES AGAINST CAIX WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR | Non-Final OA | Telix Pharmaceuticals (Innovations) Pty Ltd |
| 17220012 | Detection and Treatment of Malignant Tumours in the CNS | Non-Final OA | Targinta AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy